Egide SA recorded a reported 2.4% decrease in revenue for the first half of 2026, though on a constant currency basis the French hermetic package specialist posted a 0.7% increase. Group sales for the period totaled EUR 15.20 million.
The company highlighted a pronounced contraction in U.S. revenue. Egide USA saw sales decline by 33%, a fall the company attributed to temporary delays in customer program ramp-ups and a cessation of production at its Santier facility. Those factors materially reduced receipts from the Americas during the reporting period.
Not all segments moved in the same direction. Revenue from thermal imaging rose by 23% and now represents 55% of the group’s total revenue, providing a meaningful offset to weaknesses elsewhere. By contrast, the power segment experienced a 64% drop in revenue as the company shifted emphasis toward more strategic applications within its portfolio.
Looking ahead, Egide cautioned that business in the second half of 2026 is expected to be weaker than in the first half. Management said the pace at which backlog converts into revenue over the remainder of the year will depend heavily on the ramp-up at its Cambridge facility. That operational milestone is therefore central to revenue timing for H2.
Despite the mid-year softness and the operational disruptions noted, Egide reiterated its expectation that full-year 2026 results will show positive year-on-year growth. The company did not provide additional numerical guidance in the material supplied, instead highlighting the dependency of second-half performance on facility ramp-up and customer program progress.
Contextual note - The company’s mid-year performance reflects a mix of segment-level strength in thermal imaging and near-term operational headwinds tied to U.S. program timing and a Santier production halt. Conversion of backlog into reported sales is tied to the Cambridge facility’s increased output.